Welcome to LookChem.com Sign In|Join Free

CAS

  • or

51131-85-2

Post Buying Request

51131-85-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

51131-85-2 Usage

Description

5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol is an organic heterotetracyclic compound characterized by its unique chemical structure and potential biological activities. It belongs to the class of ellipticine derivatives, which are known for their cytotoxic and anti-tumor properties.

Uses

Used in Pharmaceutical Industry:
5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol is used as a cytotoxic and anti-tumor agent for its potential to target and inhibit the growth of cancer cells. Its chemical structure allows it to interact with cellular components, leading to the disruption of essential cellular processes in tumor cells and ultimately causing cell death.
Used in Cardiovascular Applications:
5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol is used as a cardioprotective agent for its ability to protect the heart against ischemia/reperfusion injury. 5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol may help reduce the damage caused by a lack of oxygen supply to the heart muscle and improve the overall cardiac function during and after a heart attack.

Check Digit Verification of cas no

The CAS Registry Mumber 51131-85-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,1,3 and 1 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 51131-85:
(7*5)+(6*1)+(5*1)+(4*3)+(3*1)+(2*8)+(1*5)=82
82 % 10 = 2
So 51131-85-2 is a valid CAS Registry Number.
InChI:InChI=1/C17H14N2O.ClH/c1-9-14-8-18-6-5-12(14)10(2)17-16(9)13-7-11(20)3-4-15(13)19-17;/h3-8,19-20H,1-2H3;1H

51131-85-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol

1.2 Other means of identification

Product number -
Other names ELLIPTICINE,9-HYDROXY

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:51131-85-2 SDS

51131-85-2Downstream Products

51131-85-2Relevant articles and documents

Oxidation of ellipticine with Fremy's salt under sonochemical conditions

Pautet,Formisyn,Bourgois

, p. 499 - 500 (1993)

-

Synthesis and cytotoxicity of novel bisellipticines and bisisoellipticines

Obaza-Nutaitis, Judy A.,Gribble, Gordon W.

, p. 171 - 187 (2019/07/31)

A series of bis-ellipticines 7-9 and bis-isoellipticines 10-12 tethered through the indole nitrogen was synthesized and screened for antitumor cytotoxicity in the L-1210 murine leukemia assay. Activity was only displayed by 1,10-bis(6-ellipticinyl)-?-decane (8).

SMALL MOLECULES TARGETING REPEAT r(CGG) SEQUENCES

-

, (2015/11/16)

The invention provides a series of bioactive small molecules that target expanded r(CGG) repeats, termed r(CGG)exp, that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium, binds the 5′CG/3′GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Specifically, dimeric compounds incorporating two 9-hydroxyellipticine analog structures can even more potently bind the 5′CGG/3′GGC motifs in r(CGG)exp and disrupts a toxic r(CGG)exp-protein complex. Structure-activity relationships (SAR) studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG) repeats, such as r(CGG)exp. Importantly, the compound is efficacious in FXTAS model cellular systems as evidenced by its ability to improve FXTAS-associated pre-mRNA splicing defects and to reduce the size and number of r(CGG)exp-protein aggregates.

Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases

Stiborova, Marie,Indra, Radek,Moserova, Michaela,Cerna, Vera,Rupertova, Martina,Martinek, Vaclav,Eckschlager, Tomas,Kizek, Rene,Frei, Eva

experimental part, p. 1075 - 1085 (2012/08/13)

The antineoplastic alkaloid ellipticine is a prodrug, whose pharmacological efficiency is dependent on its cytochrome P450 (P450)- and/or peroxidase-mediated activation in target tissues. The P450 3A4 enzyme oxidizes ellipticine to five metabolites, mainly to 13-hydroxy- and 12- hydroxyellipticine, the metabolites responsible for the formation of ellipticine-13-ylium and ellipticine-12-ylium ions that generate covalent DNA adducts. Cytochrome b5 alters the ratio of ellipticine metabolites formed by P450 3A4. While the amounts of the detoxication metabolites (7-hydroxy- and 9-hydroxyellipticine) were not changed with added cytochrome b5, 12-hydroxy- and 13-hydroxyellipticine, and ellipticine N 2-oxide increased considerably. The P450 3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome b5, while apo-cytochrome b5 without heme or Mn-cytochrome b5 had no such effect. The change in amounts of metabolites resulted in an increased formation of covalent ellipticine-DNA adducts, one of the DNA-damaging mechanisms of ellipticine antitumor action. The amounts of 13-hydroxy- and 12-hydroxyellipticine formed by P450 3A4 were similar, but more than 7-fold higher levels of the adduct were formed by 13-hydroxyellipticine than by 12-hydroxyellipticine. The higher susceptibility of 13-hydroxyellipticine toward heterolytic dissociation to ellipticine-13-ylium in comparison to dissociation of 12-hydroxyellipticine to ellipticine-12-ylium, determined by quantum chemical calculations, explains this phenomenon. The amounts of the 13- hydroxyellipticine-derived DNA adduct significantly increased upon reaction of 13-hydroxyellipticine with either 3′-phosphoadenosine-5′- phosphosulfate or acetyl-CoA catalyzed by human sulfotransferases 1A1, 1A2, 1A3, and 2A1, or N,O-acetyltransferases 1 and 2. The calculated reaction free energies of heterolysis of the sulfate and acetate esters are by 10-17 kcal/mol more favorable than the energy of hydrolysis of 13-hydroxyellipticine, which could explain the experimental data.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 51131-85-2